Forbion
Venture Capital. All stages.
- Stages
- Pre-Seed, Seed, Series A, Series B, Growth
- Focus
- Health & Bio, Food & Agriculture, Climate
- Invests in
- Europe, US
- Offices
- Naarden, Netherlands; Munich, Germany; Boston, United States
- Founded
- 2006
- Website
- forbion.com
- Elsewhere
About
Forbion began as ABN AMRO Capital Life Sciences, the venture arm of ABN AMRO Bank. The team later spun out as Forbion Capital Partners and shortened the name to Forbion in 2018. Co-founder Sander Slootweg is managing partner, as is Geert-Jan Mulder; general partners include Wouter Joustra, Nanna Lüneborg, Robbert van de Griendt, Alexander Hoffmann and Joy Faucher. The firm runs three fund families: Ventures, Growth Opportunities and BioEconomy. Through a joint venture with BioGeneration Ventures it also covers company formation, including FIRST, a fund that helps scientists turn research into product companies. Besides its head office it has offices in Munich and Boston. About a third of the Ventures portfolio are companies Forbion builds itself, around novel or in-licensed assets and with proven management teams. The BioEconomy fund looks for companies whose products can replace existing ones at equal or lower cost.
Notable investments
- Aiolos Bio
- Mariana Oncology
- Capstan Therapeutics
- RAPT Therapeutics
Last checked 13 November 2026. Something wrong or out of date? Write to hi@schub.tech.
Previous: Fly VenturesNext: Fortino Ventures
Building a company in Europe? Schub invests €25k for 2% and gives you a weekly 1:1 with a founder coach.
Apply to Schub